ArticleAmerican journal of translational research2025
Meta-analysis on the diagnostic value of Syndecan 2 methylation in stool for the detection of colorectal cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, and early detection is essential for improving patient survival rates. Stool-based DNA methylation indicators are among the molecular biomarkers that have shown great promise as CRC screening methods. Because of its aberrant methylation patterns in malignant cells, the gene Syndecan 2 (SDC2), which is important in cellular development and differentiation, has shown potential as a biomarker for CRC. The goal of this study is to conduct a meta-analysis to evaluate the diagnostic utility of SDC2 methylation in stool samples for the detection of colorectal cancer. The study involved a comprehensive literature search to identify all relevant studies on SDC2 methylation for CRC analysis from the beginning until 2023. Relevant studies were identified through systematic searches in Google Scholar, Web of Science, PubMed, and Scopus. STATA program and Meta Disc 1.4 were used to perform the meta-analysis. A total of 30 studies, encompassing 120 CRC cases and controls, were included. The analysis revealed the pooled sensitivity and specificity of SDC2 methylation in stool samples, as demonstrated by the area under the curve (AUC). SDC2 methylation demonstrated strong diagnostic accuracy, with significantly higher sensitivity in patients with advanced-stage CRC. SDC2 methylation offers a convenient, non-invasive diagnostic option and represents a useful biomarker for CRC screening. Even though it demonstrates a high degree of diagnostic accuracy, more research is necessary to improve test procedures and confirm outcomes across a variety of categories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.